Keywords: Liver, Liver, Hepatocellular Carcinoma, Targeted Therapy, Immunotherapy, Prognostic Prediction ·
Motivation: Biomarkers that predict the efficacy of immunotherapy-based systematic therapy remain an unmet need in HCC.
Goal(s): To establish an optimized model by integrating magnetic resonance (MR) features and CRAFITY score to predict overall survival (OS) of HCC patients treated with targeted therapy and immunotherapy.
Approach: The clinical variables and MR features were assessed by univariate and multivariate Cox regression analyses.
Results: Based on independent risk factors (Gender, intRatumoral fAt, enhancing tumor caPsule, gross growtH type and CRAFITY Score) identified by the multivariate analysis, a novel prognostic tool named GRAPH-CRAFITY Score was developed to predict OS.
Impact: A novel prognostic tool by integrating gender, MR features and laboratory tests was developed to predict OS of HCC patients treated with targeted therapy and immunotherapy, which will help oncologists for decision-making.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords